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Abstract 
 
THE EFFECT OF DEXAMETHASONE ON IL-33-MEDIATED MAST CELL 
ACTIVATION 
By Oksana Igorevna Chernushevich, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biology at Virginia Commonwealth University. 
 
University of Virginia, 2011 
 
Major Director:  John J. Ryan, Ph.D. 
Professor of Biology, Department of Biology 
 
 
Dexamethasone has been shown to inhibit IgE-mediated mast cell activation, and the 
present research investigated its role in suppressing IL-33-mediated mast cell activation. We have 
found that micromolar concentrations of Dexamethasone are capable of suppressing IL-33-
mediated mast cell cytokine production, on several genetic backgrounds, and in not only bone 
marrow derived mast cells, but also peritoneal mast cells. Intracellular staining demonstrated that 
Dexamethasone significantly reduces expression of the IL-33 receptor, T1/ST2, in mast cells; 
however, the cytokine suppression is independent of T1/ST2 downregulation. At the same time, 
Dexamethasone pretreatment significantly reduced ERK phosphorylation, but our data suggests 
that inhibition occurs even prior to ERK blockade. Finally, Dexamethasone treatment in vivo 
reduced IL-33-mediated cytokine production and neutrophil infiltration in the murine peritoneum. 
Thus, Dexamethasone, a well-established therapy for inflammatory disease, can suppress IL-33-
 
x 
 
  
mediated mast cell activation, and may therefore be effective for treating diseases now being 
attributed to IL-33 effects.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 1 
Introduction 
 
Mast cells 
Mast cells have many functions in the innate and adaptive immune response. They 
belong to the myeloid lineage of hematopoietic cells, and circulate in blood as committed 
precursors until they move to vascularized tissues for final maturation. Although they are 
found in most tissues, they are often located in areas that are in close proximity to the 
environment, such as epithelial tissues of skin, lungs, and intestine, due to their role in 
defense against parasites (Urb and Sheppard, 2012). However, they are also essential in 
IgE-mediated allergic reactions. Mast cells express high-affinity IgE receptors (FcεRI), and 
are usually activated when FcεRI binds antigen-specific IgE antibodies, leading to cross-
linkage by antigen. As a result of mast cell activation, various pre-formed and newly 
synthesized pro-inflammatory mediators are released, including histamine, bioactive lipids, 
and cytokines and chemokines (Kalesnikoff and Galli, 2008). Thus, mast cells are 
important effectors of allergic disorders, such as anaphylaxis, hay fever, allergic rhinitis, 
atopic dermatitis, eczema, and asthma (Oskeritzian et al., 2010). At the same time, mast 
cells have also been implicated in a range of other disorders, from autoimmune diseases to 
cancer, since they can elicit chemotaxis of other immune effector cells, altering 
inflammation in a complex way that leads to either protective or pathologic reactions, 
depending on the molecules secreted (Ryan et al., 2009). Thus, mast cell activation can 
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both enhance and inhibit inflammation, but the specific processes and mechanisms are not 
fully understood. 
 
IL-33-mediated mast cell activation 
Although IgE-mediated activation has been most extensively studied, many other 
molecules can activate or amplify mast cell activation, such as complement, IgG, specific 
pathogen-associated molecular patterns, and various cytokines, such as IL-33 (Moulin et 
al., 2007). 
IL-33, a member of IL-1 cytokine family, is constitutively expressed in the nucleus 
of several cell types, including epithelial cells, endothelial cells and innate immune cells 
such as macrophages and dendritic cells (Moussion et al., 2008; Prefontaine et al., 2010; 
Kurowska-Stolarska et al., 2009; Schmitz et al., 2005). It can also be induced under 
inflammatory conditions as an alarmin. Studies have shown that it is likely that IL-33 is 
released through cell necrosis or injury, as well as a response to allergens (Luthi et al., 
2009; Yoshimoto and Matsushika, 2014). IL-33 can also bind to NFκB and chromatin, 
inducing pro-inflammatory gene expression (Ali et al., 2011; Choi et al., 2012; Carriere et 
al., 2007; Saluja et al., 2015). Thus, IL-33 has a dual function as a cytokine and a 
transcription factor. 
Mature, full length IL-33, a 30-kDa protein, is a ligand for IL-33Rα (T1/ST2, also 
termed IL-1RL1), which induces signal transduction after forming a heterodimeric receptor 
complex containing IL-1RAcP. IL-1RAcP contains an intracellular TIR domain with 
adapter proteins, including MyD88, TRAF6, and IRAK4, leading to activation of the 
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NFκB and MAPK/AP-1 pathways (Luthi et al., 2009; Cayrol and Girard, 2009; Yoshimoto 
and Matsushika, 2014; Pecaric-Petkovic, 2009; Chow et al., 2010; Saluja et al., 2015). 
T1/ST2 receptor is similar to other IL-1 receptors, and is expressed on mast cells, 
basophils, eosinophils, neutrophils, T cell subsets, B-1 cells, macrophages, dendritic cells, 
and ILC2. All respond to IL-33 (Bergers et al., 1994; Moulin et al., 2007; Liew et al., 
2010; Matsushita and Yoshimoto, 2014; Yoshimoto and Matsushika, 2014).  At the same 
time, the T1/ST2 receptor exists as soluble isoform (sST2) that serves as a decoy receptor 
for IL-33. It binds IL-33 and reduces its level in the serum (Saluja et al., 2015). Elevated 
serum concentrations of sST2 have been shown to be associated with abnormal Th2 
responses and inflammatory conditions (Oshikawa et al., 2001; Kuroiwa et al., 2001; 
Moulin et al., 2007). 
T1/ST2 is highly expressed on mast cells, which respond to IL-33 by increasing 
production of Th2 cytokines, such as IL-6 and IL-13, with or without IgE-activation 
(Moulin et al., 2007; Allakhverdi et al., 2007; Iikura et al., 2007; Silver et al., 2010; Saluja 
et al., 2015; Kondo et al., 2008; Ho et al., 2007; Smithgall et al., 2008; Yoshimoto and 
Matsushika, 2014).  The resulting chemokines can recruit eosinophils, basophils, and 
neutrophils to the site of inflammation (Kondo et al., 2008; Schmitz et al., 2005; 
Kurowska-Stolarska et al., 2009; Haenuki et al., 2012; Yasuda et al., 2012; Yoshimoto and 
Matsushika, 2014). Furthermore, IL-33 can stimulate both innate and adaptive immune 
cells to increase or decrease Th2 cytokine production, leading to eosinophilic 
inflammation. Thus, IL-33 could be an attractive therapeutic target for potential treatment 
of allergic and inflammatory diseases (Yoshimoto and Matsushika, 2014).  
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Glucocorticoids 
Glucocorticoids are steroid hormones that are widely used to treat autoimmune and 
inflammatory conditions due to their anti-inflammatory and immune-suppressive 
properties (de Haij et al., 2004). Dexamethasone is a highly effective synthetic 
glucocorticoid used as a therapeutic agent for conditions such as arthritis, colitis, severe 
allergies and asthma, and in cancer therapy. Glucocorticoids act on a variety of cell types, 
including lymphocytes, eosinophils, basophils, and mast cells, but the mechanism of action 
can vary in each cell type (Ohta and Yamashita, 1999; Schleimer et al., 1981; Schleimer et 
al., 1982; Yamaguchi et al., 1994; Yamamoto and Gaynor, 2001). 
The main mechanism of action of glucocorticoids is through binding to the 
cytoplasmic glucocorticoid receptor (GR). GR dissociates from chaperone proteins, such 
as heat shock protein (hsp90) and translocates into the nucleus, where it binds DNA at 
glucocorticoid response elements in the promoter region of corticosteroid-responsive 
genes, altering their transcription (Tsai and O'Malley, 1994; Truss and Beato, 1993; Barnes 
and Adcock, 1998; Bassam and Mayank, 2012). Glucorticoids bound to their receptors can 
also interact and inhibit activities of DNA-binding transcription factors, such as AP-1 and 
NFκB, and, therefore, downregulate transcription of pro-inflammatory genes, or they can 
recruit co-repressors of certain inflammatory proteins (Karin, 1998; Ito et al., 2000; 
Bassam and Mayank, 2012; Heck et al., 1994; Kassel et al., 2004; Luecke and Yamamoto, 
2005; Oppong et al., 2013; Almawi et al., 1998; de Haij et al., 2004). 
This canonical signaling cascade cannot account for the effects of glucocorticoids 
that occur within seconds or minutes (Croxtall at al., 2000; Oppong et al., 2013), which are 
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too fast to involve transcriptional or translational inhibition. Thus, it has been proposed 
that the rapid action mechanism may involve plasma membrane and cytoplasmic activities 
of the glucocorticoid receptors (Zhou et al., 2008; Liu et al., 2007; Oppong et al., 2013). 
Certain effects of glucocorticoids in mast cells, such as decreased number of mast cells in 
tissue and decreased IgE/antigen-induced cytokine production and other responses, have 
been reported (Benhamou et al., 1986; Robin et al., 1985; Daëron et al., 1982; Wershil et 
al., 1995; Eklund et al., 1997; Finotto et al., 1997; Yamaguchi et al., 1994). However, the 
mechanism of glucocorticoid-mediated rapid effects in mast cells is lacking, as are the 
effects of glucocorticoids on IL-33-mediated activation. Our data show that 
Dexamethasone is a rapid and potent suppressor of IL-33-induced mast cell functions. 
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Materials and Methods  
Animals 
C57BL/6J and 129/SvJ mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME) and used at a minimum of 6 weeks old, with approval from the Virginia 
Commonwealth University institutional animal care and use committee (IACUC). 
 
Mouse Mast Cell Cultures  
Mouse bone marrow-derived mast cells (BMMCs) were derived by harvesting bone 
marrow aspirates from the femur of mice, followed by culture in complete RPMI (cRPMI) 
1640 medium (Invitrogen Life Technologies, Carlsbad, CA) containing 10% FBS, 2mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 1mM sodium pyruvate, and 1mM 
HEPES (all from Corning, Corning, NY), supplemented with IL-3-containing supernatant 
from WEHI-3B cells and SCF-containing supernatant from BHK-MKL cells. The final 
concentration of IL-3 and SCF were adjusted to 1ng/ml and 10ng/ml, respectively, as 
measured by ELISA. BMMC were used after 3 weeks of culture, at which point these 
primary populations are >90% mast cells, based on staining for c-Kit and FcεRI 
expression. 
 
Cytokines and reagents 
All cytokines, including IL-33, IL-3 and SCF, were purchased from Biolegend (San 
Diego, CA). APC-coupled anti-mouse IL-6, APC-coupled anti-mouse TNF, FITC-coupled 
anti-mouse CD117, and FITC-coupled rat IgG1 isotype control were purchased from 
  
 7 
Biolegend (San Diego, CA). PE-coupled rat Anti-mouse TNF, FITC-coupled rat anti-
mouse T1/ST2, mouse IgE, and purified rat anti-mouse CD16/CD32 were purchased from 
BD Biosciences (San Jose, CA). Propidium Iodide and DNP-HSA were purchased from 
Sigma-Aldrich (St. Louis, MO). Dexamethasone was purchased from Tocris Bioscience 
(Bristol, UK). ERK inhibitor (Cat#328006) was purchased from Calbiochem (EMD 
Biosciences, La Jolla, CA). 
 
Cytokine measurement 
BMMC were cultured in cRPMI 1640 with 10 ng/mL IL-3 and SCF overnight at a 
concentration of 1x10
6
 cells/mL. BMMC were washed twice in PBS, then resuspended at 
1x10
6 
cells/mL in cRPMI 1640 with 10 ng/mL IL-3 and SCF. The cells were activated with 
50 ng/mL IL-33 simultaneously with the addition of Dexamethasone or other drugs, and 
incubated for 6-18 hours at 37°C, after which supernatants were collected. Alternatively, 
cells were kept overnight at 37°C with 0.5ug/ml of IgE, washed twice with PBS and 
activated with 50 ng/ml of dinitrophenyl-conjugated human serum albumin (DNP-HSA). 
IL-6, TNF, MCP-1, and IL-13 supernatant levels were measured using ELISA kits from 
Biolegend (San Diego, CA) for IL-6, TNF, and MCP-1, and eBioscience (San Diego, CA) 
and PeproTech (Rocky Hill, NJ) for IL-13. μQuant (Bio-Tek Instruments, Inc) was used as 
ELISA plate reader. 
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Peritoneal mast cell culture 
Peritoneal lavage was performed on C57BL/6J mice. Cells were harvested and 
cultured in WEHI/BHK at 37°C for 10 days to allow for mast cell expansion. Mast cells 
were positively selected and separated using the EasySep Magnet from StemCell 
Technologies (Vancouver, BC) using c-Kit as a positive marker of mast cells. Flow 
cytometry was used as confirmation of mast cells. Cells were then washed twice with PBS 
and resuspended at 5x10
5
/ml in cRPMI with IL-3 and SCF at 10ng/ml at 37°C overnight. 
Cells were treated with either 5 M Dexamethasone or vehicle control, activated 
simultaneously with 50 ng/ml IL-33, and incubated for 16 hours at 37°C, after which 
supernatants were collected. Levels of IL-6, TNF, MCP-1, and IL-13 were measured by 
ELISA. 
 
Measurement of cytokine production due to synergy between Antigen and IL-33 
BMMC were cultured in cRPMI 1640 with 10 ng/mL of IL-3 and SCF overnight at 
a concentration of 1x10
6
 cells/mL with or without 0.5ug/ml of IgE. BMMC were washed 
twice in PBS, then resuspended at 1x10
6
 cells/mL in cRPMI 1640 with 10 ng/mL IL-3 and 
SCF and with vehicle control or 1M or 5M Dexamethasone  +/-50 ng/ml DNP-HSA and 
+/- 50 ng/ml IL-33 added to appropriate wells. The cells were incubated for 18 hours at 
37°C, after which supernatants were collected. Levels of IL-6, TNF, MCP-1, and IL-13 
were measured by ELISA. 
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Migration assay 
BMMC were cultured in cRPMI 1640 with 10 ng/mL IL-3 and SCF overnight at a 
concentration of 1x10
6
 cells/mL with 0.5 ug/ml IgE. BMMC were washed twice in PBS, 
then resuspended at 2x10
6
 cells/mL in FBS-free cRPMI supplemented with 10 mg/ml BSA 
and 2 M Dexamethasone for 1 hour. Eight m polycarbonate 24-well transwell inserts 
from Corning were coated in FBS-free cRPMI/BSA, and plates were incubated for 1 hour 
at 37° C. Bottom chambers contained 900 μL of FBS-free cRPMI with IL-3 at 1 ng/mL 
and with 50 ng/ml SCF, +/- 50 ng/ml DNP-HSA, and +/- 200 ng/ml IL-33. 200 μL of the 
previously starved BMMC supplemented with 1 ng/mL IL-3 were placed in the upper well. 
Sample were incubated for 16 hours at 37° C, after which cells migrated to the bottom 
chamber were counted using flow cytometry with propidium-iodide exclusion staining. 
Fold of media control was calculated for all groups. 
 
Flow cytometric analysis 
Cells were cultured at 1x10
6
/ml in cRPMI with IL-3 and SCF (10ng/ml each) 
overnight prior to staining. Afterwards, cells were washed in PBS twice, centrifuged and 
resuspended in PBS containing the indicated antibodies (FITC-labeled IgG, anti-c-Kit, and 
anti-T1/ST2) to assess expression of cell surface molecules. Samples were incubated at 4° 
C for 30-45 minutes, washed twice with PBS, and resuspended in 200 μl of PBS. Samples 
were then analyzed using a on a BD FACSCalibur (BD Biosciences).  
To assess the expression of intracellular IL-6 and TNF, cells were resuspended in 
cRPMI containing IL-3 and SCF at 10 ng/ml and 1 M Dex or vehicle control and 
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incubated overnight at 37°C. Cells were then activated with 50 ng/ml IL-33 for 90 min at 
37°C, treated with 5 uM monensin for 5-6 hours at 37°C, washed twice with PBS and 
stained with anti-T1/ST2 or IgG for 40 min at 4°C.The cells were then washed twice with 
PBS and fixed in PBS containing 4% paraformaldehyde for 20 min at room temperature, 
washed with PBS, and stored overnight at 4°C. The cells were then pelleted and 
resuspended in saponin buffer (PBS, 0.1% BSA, 0.01M HEPES, 0.5% saponin) for 20 
minutes at room temperature. Cell pellets were then incubated for 40 min at 4°C with 
indicated antibodies (PE-TNF, APC-TNF, APC-IL-6, or PE-cKit) diluted in saponin 
buffer. Finally, cells were washed with staining buffer and resuspended in 200 L PBS. 
 
Western Blotting 
Cells were cultured at 2x10
6
/ml in cRPMI with IL-3 and SCF at 10ng/ml with 2 
M Dexamethasone or vehicle control for 18 hours. Cells were then starved for 4 hours in 
cRPMI lacking growth factors prior to activation with 100 ng/ml of IL-33. Cells were then 
lysed in Lysis Buffer (Cell Signaling Technology) supplemented with 1.5 ProteaseArrest 
(G-Biosciences, Maryland Heights, MO). Protein concentration was determined using the 
Pierce BCA protein assay kit (Thermo Scientific). Proteins were separated on 4-20% Mini-
Protean TGX Gels (Bio-Rad, Hercules, CA) using 25 μg of total protein per sample. 
Transfer was done onto nitrocellulose membranes, which were then blocked for 1 hour at 
room temperature with 2% BSA in PBS. Membranes were rinsed in PBS and then 
incubated overnight at 4°C in 0.1% TWEEN in PBS containing 2% BSA and primary 
antibody diluted 1:1000. Membranes were washed the next day with 0.1% TWEEN in PBS 
  
 11 
every 5 minutes for a total of 30 minutes, then incubated with a 1:10,000 dilution of either 
goat anti-rabbit or goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA). 
Membranes were rinsed a final time before being read on an Odyssey CLx infrared scanner 
(Li-Cor, Lincoln, Nebraska).  
 
ERK Inhibitor 
ERK inhibitor, Cat#328006 from Calbiochem (EMD Biosciences, La Jolla, CA), 
was solubilized in dimethyl sulfoxide (DMSO), and used at working concentrations of 50 
M. It was added to cultures one hour prior to activation with 50 ng/mL of IL-33. 
Supernatants were collected 6 hours later and ELISAs were run to determine cytokine 
production. 
 
Effect of Dexamethasone on VDR-KO or miR-155KO mast cells 
BMMC from VDR-KO, miR-155 KO and control C57BL/6J mice were cultured in 
cRPMI 1640 with IL-3 and SCF, 10 ng/ml each, overnight at 37°C at a concentration of 
1x10
6
 cells/mL, and then treated with Dexamethasone. Where indicated, 1,25(OH)2 
vitamin D3 (hence referred to as Vitamin D) at 1x10
-8
M was added just prior to activation 
with 50 ng/ml IL-33. The cells were incubated for 18 hours at 37°C. Supernatants were 
collected, and levels of IL-6, TNF, MCP-1, and IL-13 were measured by ELISA. 
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Measurement of neutrophil recruitment in vivo 
 C57BL/6J mice, 12 weeks or older, were injected i.p. with 2 ml PBS or 
Dexamethasone (2mg/kg) one hour prior to i.p. injection with 1 g IL-33. Six hours later, 
peritoneal lavage and cardiac puncture were performed. Cells were stained with antibodies 
against Gr1, Mac1, Ly6G and c-Kit prior to analysis by flow cytometry. Plasma was 
analyzed by ELISA. 
 
Statistics 
Data presented are the mean ± SEM of at least 3 independent experiments. P-values 
were calculated with GraphPad Prism software by paired or unpaired, two-tailed Student’s 
t Test as appropriate. The IC50 values were calculated from the dose–response curves. P-
values of <0.05 were considered statistically significant. 
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Results 
 
The effect of Dexamethasone on IL-33 activated BMMC 
There have been many studies of Dexamethasone effects on IgE-activated mast 
cells, but no data on Dexamethasone effects on IL-33-mediated mast cell function have 
been published (Oppong et al., 2013). To determine if Dexamethasone affects IL-33-
induced cytokine production, we conducted a dose response (Figure 1) and time course 
(Figure 2), with assays for IL-6, TNF, MCP-1, and IL-13. We pretreated C57BL/6 BMMC 
for 24 hours with Dexamethasone, then activated with 50 ng/ml IL-33.  We also added 
Dexamethasone after activation with IL-33 at several time points (Figure 3). The data show 
that the effect of Dexamethasone on mast cell cytokine production is dose-dependent with 
24 hour pretreatment with Dexamethasone, and the effect of Dexamethasone decreases 
when it is administered for longer periods or after IL-33 activation. Interestingly, the 
suppressive effects were even stronger when Dexamethasone was added simultaneously 
with IL-33.  
 
Genetic background does not alter responsiveness to Dexamethasone 
Our lab has recently found that genetic background can alter responsiveness to 
statin drugs, TGF1, and IL-10 (Fernando et al., 2013; Speiran et al., 2009, and 
unpublished data).  C57BL/6 mice, the strain used to this point, are Th1-prone. We 
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conducted a dose response on 129/SvJ mice, which are Th2-prone, and found that the IC50 
values for Dexamethasone-mediated IL-6, TNF, MCP-1, and IL-13 suppression were not 
significantly different from C57BL/6J BMMC, using 24-hour pretreatment with 
Dexamethasone prior to IL-33 activation (Table 1). 
 
Dexamethasone decreases pro-inflammatory cytokines ex vivo 
In the experiments so far, we demonstrated that Dexamethasone affects BMMC 
cultured in vitro. To determine if these effects are similar among mast cells differentiated 
in vivo, we used peritoneal mast cells.  Mast cells were treated with 5 M Dexamethasone 
and activated with 50 ng/ml of IL-33. Our data demonstrated that Dexamethasone 
suppresses production of IL-6, TNF, MCP-1, and IL-13 from IL-33-activated peritoneal 
mast cells similarly to BMMC (Figure 4). 
 
Dexamethasone suppresses IL-33-mediated amplification of IgE-induced cytokine 
production 
It has been shown in Andrade’s article that IL-33 can synergize with IgE/antigen to 
increase mast cell cytokine production (Andrade et al., 2011). Since IL-33 could therefore 
worsen the symptoms and severity of allergic and autoimmune conditions, we determined 
if Dexamethasone suppresses this synergy. As shown in Figure 5, Dexamethasone 
suppressed IgE/antigen- and IL-33-induced cytokine production, and greatly reduced the 
cooperativity of these two stimuli. 
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Dexamethasone blocks IL-33 enhancement of Ag-induced migration 
Increased migration of mast cells toward inflammation sites is associated with 
various inflammatory conditions (Ishizuka et al., 2001). Because IgE-coated mast cells 
migrate toward antigen, and IL-33 enhances antigen-mediated cytokine production, we 
determined if IL-33 also increases antigen-induced migration, and if Dexamethasone is 
capable of suppressing it. We show in Figure 6 that IL-33 alone did not elicit BMMC 
migration, but enhanced IgE/antigen-mediated mast cell migration. Moreover, 
Dexamethasone did not reduce antigen-mediated migration, but reversed the effects of IL-
33.  
 
Dexamethasone suppresses IL-33 stimulated cytokine protein production 
We have shown that Dexamethasone suppresses IL-33-mediated cytokine 
secretion. To determine if this coincided with a reduction in total cytokine protein 
production, we employed intracellular staining and flow cytometry. Our data showed that 
Dexamethasone suppressed intracellular IL-6 and TNF production (Figure 7).  
 
Dexamethasone downregulates surface expression of IL-33R subunit T1/ST2, depending 
on time of Dexamethasone exposure 
To determine if the suppressive effects of Dexamethasone are due to altered 
T1/ST2 receptor expression, we conducted a dose response of Dexamethasone for 24 hours 
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and assessed T1/ST2 expression by flow cytomentry. Dexamethasone dose-dependently 
reduced T1/ST2 surface expression with 24 hour pretreatment (Figure 8).  
To determine a cause for the differential cytokine production caused by shorter 
exposure to Dexamethasone, we assessed changes in surface receptor levels of T1/ST2 and 
c-Kit using flow cytometry. We investigated the effect of Dexamethasone on c-Kit 
receptor expression since it has been shown that BMMC cultured with SCF (the c-Kit 
ligand) increase cytokine production, and one paper suggested that IL-33 may signal partly 
through c-Kit (Drube et al., 2010). Cells were cultured in Dexamethasone for either 6, 4, or 
0 hours and then stained for T1/ST2 and c-Kit surface expression (Figure 9). The results 
showed a modest decrease in T1/ST2 and c-Kit surface expression at these shorter time 
points.  
 
Receptor downregulation does not correlate with cytokine suppression due to 
Dexamethasone 
Next we assessed if the cytokine suppression observed with intracellular staining 
corresponded with T1/ST2 downregulation. As shown in Figure 10, cells expressing 
different levels of T1/ST2 do not have differences in cytokine production within the 
Dexamethasone-treated population, similar to the vehicle-treated population. Therefore, 
there is no correlation between T1/ST2 suppression and reduced cytokine production, 
suggesting that cytokine suppression is independent of T1/ST2 downregulation. 
 
Dexamethasone decreases IL-33-mediated ERK phosphorylation  
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To begin determining the effects of Dexamethasone on IL-33 signaling, we 
investigated the MAPK cascade. Western blot analysis was performed on cells receiving 
Dexamethasone treatment simultaneously with IL-33 activation and on those receiving 18 
hour Dexamethasone pretreatment before IL-33 activation.  After normalization to vehicle 
controls, these experiments showed that 18 hour Dexamethasone pretreatment compared to 
vehicle significantly reduced phosphorylated ERK (Figure 11). JNK, p38, and NFB p65 
were not significantly altered by 18 hour Dexamethasone pretreatment. Further, the 
simultaneous addition of Dexamethasone with IL-33 activation resulted in no changes in 
phosphorylation of ERK, JNK, or p65.   
 
ERK2 inhibitor mimics Dexamethasone effect on IL-33 activation 
The decrease in ERK phosphorylation in western blot analysis correlated with the 
ability of Dexamethasone pretreatment to reduce IL-33-mediated cytokine secretion. To 
determine if blocking this pathway alone was sufficient to mimic the effects of 
Dexamethasone, C57BL/6J BMMC were treated with 50 M ERK2 inhibitor, which acts 
by binding to ERK2 and preventing its interaction with protein substrates. We found that 
IL-33-induced secretion of IL-6, TNF, IL-13 and MCP-1 was significantly reduced, 
regardless of whether the cells were treated simultaneously with IL-33 activation or 
pretreated with the ERK2 inhibitor for 1 hour prior to activation (Figure 12). Thus, 
Dexamethasone effects on ERK phosphorylation could be functionally important. 
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VDR-KO mast cells are less responsive to Dexamethasone, and Vitamin D enhances 
responsiveness to Dexamethasone  
 It has been shown that Vitamin D (1,25-dihydroxyvitamin D3) can affect immune 
responses. For example, vitamin D can inhibit IgE-mediated mast cell activation, while 
VDR KO BMMC are hyperresponsive to IgE (Yip et al., 2014). No data on the effects of 
Vitamin D in IL-33 signaling have been published. We compared the effect of 
Dexamethasone on VDR-KO mice and control BMMC activated with IL-33, and how 
vitamin D alters these effects. Our studies showed that VDR-KO BMMC were not more 
responsive to IL-33 than WT control BMMC. VDR KO BMMC were slightly but 
significantly less responsive to Dexamethasone. Vitamin D alone, given simultaneously 
with IL-33, did not suppress IL-6 secretion from WT or VDR KO BMMC. Vitamin D did 
enhance Dexamethasone-mediated suppression of IL-33. This effect was lost in VDR KO 
BMMC as judged by IC50 values (Figure 13). These data suggest that Vitamin D can act 
through VDR to enhance the effects of Dexamethasone.  
 
miR-155 KO mast cells are less responsive to Dexamethasone than WT  
 MicroRNAs (miRNAs) are small regulatory molecules that can control the 
translation of target mRNAs and, thus, regulate various biological processes at a 
posttranscriptional level. miR-155 has been shown to possess anti-inflammatory properties 
in mast cells activated with IgE (Biethahn et al., 2014). We assessed the effects of 
Dexamethasone on wild type and miR-155-KO BMMC. Our data showed that miR-155-
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KO BMMC were significantly less responsive to Dexamethasone, based on IC50 values 
(Figure 14). These data suggest that miR-155 expression is partly required for 
Dexamethasone effects.  
 
Atorvastatin enhances Dexamethasone responsiveness in IL-33-activated mast cells 
Atorvastatin is a medication that blocks the production of cholesterol, and is often 
used in combination with other drugs. Our lab recently found that Atorvastatin suppresses 
IL-33-mediated cytokine production (unpublished data). Thus, we determined if addition 
of Atorvastatin would increase Dexamethasone effects on mast cells. BMMC were 
pretreated with 10 M Atorvastatin for 24 hours and then activated with 50 ng/ml of IL-33 
+/- simultaneous Dexamethasone treatment. Our studies showed that Atorvastatin 
significantly enhanced mast cell responsiveness to Dexamethasone (Figure 15). 
 
Dexamethasone blocks Il-33-mediated neutrophil recruitment 
 In order to demonstrate that Dexamethasone effects are consistent in vivo, we 
measured IL-33-mediated cytokine production and neutrophil recruitment. This effect was 
recently published to be mast cell-dependent (Enoksson et al., 2013). Our data showed that 
Dexamethasone significantly suppressed neutrophil recruitment by mast cells in C57BL/6J 
mice after 1 hour activation with 1 g of IL-33, injected intraperitoneally. Dexamethasone 
also significantly suppressed serum IL-6 levels in the same mice (Figure 16). 
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Discussion 
Dexamethasone and other synthetic glucocorticoids have been effectively used in 
the treatment of inflammatory disorders, particularly allergy, since they suppress the 
effector functions of many different types of immune cells (Oppong et al., 2013; 
Yamaguchi et al., 1994). This leads to alleviation of the severity of allergic inflammation 
in various conditions, such as asthma and allergic rhinitis (Rumsaeng et al., 1997) 
At the same time, IL-33 has been shown to stimulate mast cells and promote the 
Th2 immune response (Moulin et al., 2007). Numerous studies demonstrated IL-33’s role 
in inflammatory diseases, including asthma (Jung et al., 2013). Thus, IL-33 is a potential 
therapeutic target in chronic inflammation (Jung et al., 2013; Ciccia et al., 2013). Because 
mast cells play such an important role in many disorders, including asthma, it is imperative 
to not only find the appropriate inhibitor of mast cell activation, but also understand its 
mechanism of action. 
This study provides new information on Dexamethasone effects on IL-33-activated 
mast cells. We established that Dexamethasone suppresses pro-inflammatory cytokine 
production with 24 hour pretreatment prior to IL-33 activation, and that Dexamethasone 
effects are even more pronounced when added simultaneously with IL-33. We find IC50 
values ranging from 9 nM for IL-6 suppression to 32 nM for MCP-1. We recently found 
that genetic background can alter mast cell responsiveness to statin drugs, with C57BL/6 
and 129/SvJ BMMC showing widely varying sensitivity (unpublished findings). However, 
Dexamethasone responses were similar among BMMC from these backgrounds, when 
  
 21 
assessing IC50 values for suppression of IL-33-induced IL-6, TNF, MCP-1, and IL-13 
production. 
Because bone marrow-derived mast cells are not considered fully mature, and are 
differentiated in vitro, we assessed Dexamethasone effects on peritoneal mast cells 
expanded in culture. These cells are known to retain most of the morphological, 
phenotypic, and functional features of peritoneal mast cells (Malbec et al., 2007). 
Dexamethasone significantly suppressed IL-33 mediated cytokine production in peritoneal 
mast cells, arguing that these effects are physiologically relevant.  
IL-33 has been shown to synergize with FcRI to increase mast cell cytokine 
production (Andrade et al., 2011), and thus worsen allergic inflammation. In this study we 
confirmed that IL-33 synergizes with antigen and demonstrated that Dexamethasone not 
only inhibited antigen- and IL-33-induced cytokine production, but also the cooperativity 
of these two signals. This is important because it suggests that Dexamethasone therapy 
may be efficacious in a setting where both IL-33 and IgE are activating mast cells, which is 
likely the case in vivo.  
Increased migration and accumulation of mast cells at sites of inflammation are 
common for many inflammatory conditions (Oppong et al., 2013). It has previously been 
shown that antigen induces mast cell migration (Ishizuka et al., 2001), but no one has yet 
reported that IL-33 effects on this process. Our data demonstrated that IL-33 significantly 
increases antigen-induced migration and that Dexamethasone suppresses it. Further studies 
revealing the mechanism by which migration is reduced are needed. 
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We also investigated the mechanism by which Dexamethasone affects IL-33 
signaling. Our studies showed that with 24 hour pretreatment, Dexamethasone suppresses 
intracellular levels of IL-6 and TNF, but this does not markedly correlate with T1/ST2 
receptor downregulation, which was moderately suppressed by 24 hour pretreatment. It has 
recently been published that IL-33-induced signaling via T1/ST2 cross-activates c-Kit, 
(Drube et al., 2010). We demonstrated that c-Kit receptor expression is slightly diminished 
by Dexamethasone, but this required at least 4 hours of pretreatment. Thus, receptor 
downregulation cannot account for the immediate effects of Dexamethasone, and also do 
not correlate with its longer term effects.  
IL-33 is known to activate MAP3K signaling (Moulin et al., 2007), that leads to 
JNK, ERK, and p38 phosphorylation in mouse and human mast cells (Kunisch et al., 2012; 
Saluja et al., 2015). The MAP3K TAK1 has been postulated to lie upstream of NFB in 
IL-33 signaling as well (Andrade et al., 2011). We performed western blot analysis, and 
found that Dexamethasone significantly reduced ERK phosphorylation with 18 hour 
pretreatment.  Correspondingly, ERK inhibitor treatment mimicked Dexamethasone effects 
on IL-33-mediated IL-6, TNF, MCP-1, and IL-13 production. However, none of these 
molecules were altered when Dexamethasone was added simultaneously with IL-33. 
Collectively these data suggest that ERK blockade may be a means by which 
Dexamethasone exerts its longer term effects, but that inhibition can occur by more than 
one mechanism. 
Vitamin D is emerging as an important player in the pathogenesis of allergic 
diseases, particularly in asthma, due to its ability to suppress Th1 and Th2 responses. Many 
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tissues express vitamin D receptor (VDR), including brain, colon, breast and immune cells, 
such as mast cells (Aranow, 2011; Bikle, 2008). Studies have shown that vitamin D (1,25-
dihydroxyvitamin D3) can affect the immune responses, such as inhibiting IgE-mediated 
mast cell activation, and that VDR KO BMMC are hyperresponsive to IgE (Yip et al., 
2014; Aranow 2011).  Furthermore, low serum vitamin D levels correlate with higher 
steroid use among patients, and higher expression of vitamin D leads to better suppression 
of TNF-alpha production by Dexamethasone (Searing and Leung, 2010). However, there 
have also been some studies showing that Vitamin D receptor (VDR)-deficient mice fail to 
develop experimental allergic asthma (Wittke et al., 2004).  Thus, more work is needed to 
elucidate such a complex mechanism. In our work, by comparing suppression of cytokine 
production in BMMC derived from VDR-KO and WT mice, we concluded that VDR-KO 
mast cells are less responsive to Dexamethasone, implying that its effects are partially 
through VDR in IL-33-activated mast cells. Also, vitamin D addition improved 
Dexamethasone responsiveness in wild type but not VDR-KO BMMC, suggesting that 
VDR is the main receptor by which vitamin D affects IL-33-activated mast cells.  
Mast cells have been shown to be affected by miRNAs, particularly miR-155, 
which was recently shown to suppress PI3K-mediated signals downstream of FcRI 
(Biethahn et al., 2014). Dexamethasone has been shown to upregulate miR-155 in MDSCs, 
but no studies have been done in mast cells activated with IL-33 (Biethahn et al., 2014; Li 
et al., 2014). We found that miR-155 KO BMMC were less responsive to Dexamethasone 
than WT BMMC, implying that miR-155 might play a role in Dexamethasone effects on 
mast cell activated with IL-33. Further investigation is warranted. Our current studies show 
  
 24 
that miR-155 is constitutively expressed in BMMC, but that its levels are unchanged by 
Dexamethasone under our conditions (not shown). This suggests that baseline miR-155 
may serve a suppressive role that is required for full responsiveness to Dexamethasone. 
 Combination drug therapy is common, so it is clinically important to understand 
how various drugs may enhance or suppress Dexamethasone effects. Atorvastatin is a 
widely used statin that blocks cholesterol production. Our lab has recently found that 
Atorvastatin inhibits IL-33-mediated mast cell activation. Thus, we treated BMMC with 
Atorvastatin in addition to Dexamethasone and found that the addition of Atorvastatin 
enhanced mast cell suppression, as assessed by IL-33-induced pro-inflammatory cytokine 
production. Since statins are already being used as an add-on therapy for allergic disease, 
understanding how Dexamethasone efficacy can be improved by statin therapy could be 
immediately relevant to patient therapy. 
Finally, located in various vascularized tissues close to the external environment, 
mast cells are known for increasing the vascular permeability and attracting leukocytes, to 
sites of inflammation (Brown and Hatfield, 2012). Although it has been shown that 
glucocorticoids are capable of inhibiting IgE-mediated neutrophil recruitment by mast cells 
(Schramm and Thorlacius, 2004), no one reported the same for IL-33-activated mast cells. 
We showed that Dexamethasone treatment inhibited IL-33-mediated neutrophil 
recruitment and IL-6 production in vivo. These data support our in vitro findings, 
suggesting that IL-33 effects can be mitigated by Dexamethasone vivo. Collectively, our 
data show that Dexamethasone is an effective means of antagonizing IL-33-mediated mast 
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cell activation, supporting its use in allergic disorders in which IL-33 is now proposed as 
an exacerbating factor. 
Collectively our data show that Dexamethasone is an effective means of 
suppressing IL-33-induced mast cell activation in vitro and in vivo. Its effects may be 
mediated in part by suppressing T1/ST2 signaling, specifically ERK activation. How 
Dexamethasone effects are altered by vitamin D levels and other drugs such as statins 
could be clinically relevant and fundamentally instructive. These data support the use of 
steroids for mast cell-driven diseases in which IL-33 may be an inflammatory mediator. 
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Table 1: IC50 values (M) for Dexamethasone-mediated suppression of 
IL-33-induced cytokine production on two genetic backgrounds. 
 
 BL/6 129 
IL-6 0.009 0.0063 
TNF- α 0.017 0.024 
MCP-1 0.032 0.047 
IL-13 0.005 0.004 
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Figure 1. Dexamethasone blocks IL-33-mediated cytokine production with 24 hour 
pretreatment. C57BL/6J BMMC were cultured in IL-3 and SCF overnight, with 24 hours 
pretreatment of Dexamethasone at concentrations indicated, then activated with IL-33 for 
16 hours. Supernatants were collected and assessed by ELISA to determine cytokine 
concentrations. The results are expressed as the mean ± SEM of at least 3 independent 
experiments conducted in triplicate. 
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Figure 2E       Figure 2F 
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0 2 4 6 8
0
1000
2000
3000
4000
Dex
Vehicle
Hours after Dex treatment
IL
-6
 (
p
g
/m
L
)
0 2 4 6 8
0
10
20
30
40
50
Dex
Vehicle
Hours after Dex treatment
T
N
F
-a
 (
p
g
/m
L
)
0 2 4 6 8
0
100
200
300
400
Dex
Vehicle
Hours after Dex treatment
M
C
P
 -
 1
 (
p
g
/m
L
)
0 2 4 6 8
0
500
1000
1500
Dex
Vehicle
Hours after Dex treatment
IL
-1
3
 (
p
g
/m
L
)
30 
  
35 
 
 
Figure 2. Time course of Dexamethasone-mediated suppression of IL-33 stimulation. 
BMMC’s were cultured in IL-3 and SCF, with or without Dexamethasone or vehicle for 
the stipulated time periods, then activated with IL-33 for 8-18 hours. For the post-
treatment, Dexamethasone was added at indicated time periods after IL-33 activation. 
Supernatants were assessed by ELISA to determine cytokine concentrations. The results 
are representative of 3 independent experiments conducted in triplicate. 
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Figure 3A          Figure 3B 
 
  
 
Figure 3C            Figure 3D 
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Figure 3. Dexamethasone blocks IL-33-mediated cytokine production without 
pretreatment. C57BL/6J BMMC were cultured in IL-3 and SCF overnight followed by 
Dexamethasone at the indicated concentrations, added simultaneously with IL-33. 
Supernatants were collected after 16 hours, and assessed by ELISA to determine cytokine 
concentrations. The results are expressed as the mean ± SEM of at least 3 independent 
experiments conducted in triplicate. 
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Figure 4A      Figure 4B 
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Figure 4. Dexamethasone decreases IL-33-induced pro-inflammatory cytokine 
production ex vivo. Peritoneal mast cells treated with either 5 uM Dexamethasone or 
vehicle, simultaneously with 50 ng/ml IL-33. Supernatants were collected after 16 hours 
and assessed by ELISA to determine cytokine concentrations. The results are 
representative of experiments performed twice in triplicate. * p<0.05, ** p<0.01, 
***<p<0.0005 
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Figure 5. Dexamethasone suppresses the enhancing effects of IL-33 on FcεRI-
mediated activation. BMMC were cultured in cRPMI IL-3 and SCF with or without 
0.5ug/ml of IgE overnight prior to the addition of 1uM of Dexamethasone  +/-50 ng/ml 
DNP-HSA and 50 ng/ml IL-33. The cells were incubated for 18 hours, after which 
supernatants were assessed by ELISA. The results are representative of experiments 
performed twice in triplicate. * p<0.05, ** p<0.01, ***<p<0.0005 
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Figure 6 
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Figure 6. Dexamethasone blocks IL-33-mediated enhancement of Ag-induced 
migration. C57BL/6J BMMC were assessed for migration in response to Antigen as 
described in Materials and Methods. Fold migration is based on comparison to media alone 
samples. The results are expressed as the mean ± SEM of 2 independent experiments.  
* p<0.05, ** p<0.01, ***<p<0.0005 
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Figure 7. Dexamethasone suppresses IL-33 stimulated cytokine production (in-cell 
staining). C57BL/6J BMMC were cultured in IL-3 and SCF +/- Dexamethasone or vehicle 
for 24 hours. The cells were then activated with IL-33 for 90 minutes prior to the addition 
of monensin for 6 hours and fixation. Cells were then permeabilized stained to detect the 
indicated cytokines. Example dot plots are shown on the left. Summary of changes in 
geometric mean fluorescent intensity (gMFI) and percent positive is shown on the right. 
The results are representative of experiments performed twice in triplicate. * p<0.05,  
** p<0.01, ***<p<0.0005 
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Figure 8A 
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Figure 8. 24-hour Dexamethasone treatment downregulates ST2 surface expression. 
C57BL/6J BMMC were treated with vehicle or Dex at the indicated concentrations for 24 
hours, then stained to detect ST2 surface expression was measured by flow cytometry. The 
results are representative of experiments performed twice in triplicate. * p<0.05,  
** p<0.01, ***<p<0.0005 
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Figure 9A 
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Figure 9. Short term Dexamethasone treatment does not downregulate ST2 or c-Kit 
surface expression. C57BL/6 BMMC were treated with Vehicle or Dexamethasone at 5 
μM for 0-6 hours. Surface expression of A) T1/ST2 and B) c-Kit was measured by flow 
cytometry. The data are representative of experiments performed twice in quadruplicate.  
* p<0.05, ** p<0.01, ***<p<0.0005 
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Figure 10. Receptor downregulation does not correlate with Dexamethasone–
mediated cytokine suppression. C57BL/6J BMMC were cultured in IL-3 and SCF +/- 
Dexamethasone or vehicle for 24 hours. The cells were then activated with IL-33 for 90 
minutes prior to the addition of monensin for 6 hours, then fixed in 4% paraformaldehyde. 
Cells were permeabilized in saponin buffer stained to detect ST2, TNF- α and IL-6. The 
results are representative of 3 independent experiments conducted in triplicate. 
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Figure 11. Dexamethasone decreases IL-33-mediated ERK phosphorylation.  A) 18 
hour pretreatment with Dex. B) ph ERK/total ERK normalized to the loading control, with 
18 hour Dex pretreatment. The results are expressed as the mean ± SEM of 2 independent 
experiments. C) Simultaneous addition of Dex and IL-33 to cells. * p<0.05, ** p<0.01, 
***<p<0.0005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
  
35 
 
 
 
 
 
   Figure 12A             Figure 12B 
 
  
 
         Figure 12C             Figure 12D 
 
 
 
 
 
 
 
None Vehicle Dex Vehicle Inh
0
2000
4000
6000
8000
10000
***
***
IL
-6
 (
p
g
/m
l)
None Vehicle Dex Vehicle Inh
0
100
200
300
400
***
***
T
N
F
-a
 (
p
g
/m
L
)
None Vehicle Dex Vehicle Inh
0
500
1000
1500
2000
2500
***
***
M
C
P
 -
 1
 (
p
g
/m
L
)
None Vehicle Dex Vehicle Inh
0
1000
2000
3000
4000
***
***
IL
-1
3
 (
p
g
/m
L
)
52 
  
 52 
Figure 12. ERK Inhibitor treatment mimics Dexamethasone effects on IL-33-induced 
cytokine production. C57BL/6J BMMC were cultured in IL-3 and SCF +/- ERK inhibitor 
for 1 hour prior to IL-33 activation. The cells were incubated for 18 hours at 37°C, after 
which supernatants were analyzed by ELISA to detect cytokine secretion kits. The results 
are representative of experiments done twice in triplicate. * p<0.05, ** p<0.01, 
***<p<0.0005 
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Figure 13. VDR-KO mast cells are less responsive to Dexamethasone, and vit D 
enhances responsiveness to Dex in WT cell. BMMC from VDR-KO and WT C57BL/6J 
mice were cultured in cRPMI with IL-3 and SCF and then treated with Dexamethasone 
(0.01, 0.005, 0.001, 0.0001uM) +/- Vitamin D, and simultaneously activated with IL-33. 
The cells were incubated for 18 hours at 37°C, after which supernatants were collected. 
Levels of IL-6 were measured by Elisa kits. The results are representative. * p<0.05,  
** p<0.01, ***<p<0.0005 
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Figure 14. miR-155 KO mast cells are less responsive to Dexamethasone. BMMC from 
miR155-KO and WT C57BL/6J mice were cultured in cRPMI with IL-3 and SCF and then 
treated with Dexamethasone (0.1, 0.01, 0.001uM) and activated with IL-33 6 hours later. 
The cells were incubated for 18 hours at 37C, and then the supernatants were collected, 
and levels of IL-6, TNF-α, MCP-1, and IL-13 were measured by Elisa kits (as described 
above). The cells were incubated for 18 hours at 37°C, after which supernatants were 
collected. Levels of IL-6, TNF-α, are MCP-1 were measured by Elisa kits. The results are 
representative. * p<0.05, ** p<0.01, ***<p<0.0005 
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Figure 15. Atorvastatin enhances Dexamethasone responsiveness in IL-33-activated 
mast cells. C57BL/6J BMMC were cultured in cRPMI with IL-3, SCF and 10 uM 
Atorvastatin for 24 hours and then treated with Dexamethasone (0.1, 0.01, 0.001uM) and 
simultaneously activated with IL-33. The cells were incubated for 18 hours at 37°C, after 
which supernatants were collected. Levels of IL-6 and MCP-1 were measured by Elisa 
kits. The results are representative. * p<0.05, ** p<0.01, ***<p<0.0005 
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Figure 16. Dexamethasone blocks Il-33-mediated neutrophil recruitment. C57BL/6J 
mice, 12 weeks or older, were injected i.p. with 2 ml PBS or Dexamethasone (2mg/kg) 
with or without 1 ug of IL-33 that was injected in 1 hour, following by peritoneal lavage 
and Flow cytometry. Cells were stained with Gr1, Mac1, LysG and c-kit antibodies. A) % 
Neutrophil recruitment (Gr1+Mac1+) B) SerumIL-6. The results are representative of 
experiments done twice in triplicate. * p<0.05, ** p<0.01, ***<p<0.0005 
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